Skip to search boxSkip to navigationSkip to main content

Protracted cognitive effects produced by clonidine in Macaca nemestrina performing a delayed matching task

  • Jerry J. Buccafusco
    ,
  • Scott J. Webster
    ,
  • ,
  • Nancy Kille
    ,
  • Donna Blessing
  • VA Medical Center
    ,
  • Medical College of Georgia
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Introduction: The α2-adrenergic receptor agonist clonidine was examined for its ability to improve working memory in monkeys. Materials and methods: Clonidine (0.116-34.8 μg/kg) was administered to six pigtail macaques in their performance of a computer-assisted delayed matching-to-sample (DMTS) task. Results and discussion: During DMTS sessions initiated 1 hour after dosing, there was a slight improvement in mean task accuracy (long delay trials; 0.116-μg/kg). On the following day, there was continued and added improvement in accuracies associated with the long delay trials. On the day following 1.16-μg/kg, the entire memory retention curve was shifted to the right of vehicle. When the animals were again tested 48 hours after dosing (no pretreatment), these two patterns of task enhancement were continued and enhanced. Mean task accuracy associated with long delay trials was significantly increased by 14.2% trials correct when animals were originally treated with 0.116-μg/kg of clonidine. Mean task accuracy associated with medium delay trials was significantly increased by 11.8% trials correct when animals were treated with 1.16-μg/kg. On the sixth day after clonidine, task accuracies were still significantly improved during medium delay trials after 0.116-μg/kg. Median sample and choice latencies were not significantly influenced by clonidine treatment. These findings are consistent with the ability of clonidine to induce a protracted improvement in aspects of working memory. Conclusion: Early (attentional) and late (retention) components of memory appeared to be differentially sensitive to the dose of clonidine. Central α2-adrenergic receptors should be considered legitimate drug targets for future compound development for cognition enhancement.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 477-485 (9 pages)

Journal (Volume, Issue Number)

Psychopharmacology (Volume 202, Issue 1-3)

Publication milestones

  • Published - 01/2009

Publication status

Published - 01/2009

ISSN

0033-3158

Publication IDs

  • Scopus: 59449088302
  • PubMed: 18784917
  • ORCID: /0000-0003-2071-4767/work/68251914

Publication metrics

Metrics

Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
SciVal
FWCI
1.05
SciVal
Author count
5
SciVal
citations
9
SciVal
Paper percentile
60
Scopus
citations

PlumX, opens in new tab

Citation count
10
Captures
21

Funding Details

Acknowledgements This study was supported by Pfizer and by the Office of Research and Development, Department of Veterans Administration. The authors would also like to thank primate veterinarian Dr. Nancy Rodriguez for her clinical expertise pertaining to the care of our nonhuman primate subjects.
FundersFunding numbers
US Department of Veterans Administration
-
Pfizer
-
ORD
-